Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.

被引：0
|
作者：
Kapar, Caner
Tugcu, Volkan
Sahin, Selcuk
Guler, Haydar
Kilickap, Saadettin
Tural, Deniz
机构：
[1] Bakirkoy Res & Educ Hosp, Istanbul, Turkiye
[2] Istinye Univ, Dept Urol, Istanbul, Turkiye
[3] Bakirkoy Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[4] Kanuni Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[5] Istinye Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye
[6] Univ Hlth Sci, Dept Med Oncol, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17074
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study
    Chowdhury, Simon
    Bjartell, Anders
    Agarwal, Neeraj
    Chung, Byung H.
    Given, Robert W.
    Gomes, Andrea J. Pereira de Santana
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Soto, Alvaro Juarez
    Uemura, Hirotsugu
    Ye, Ding-Wei
    Brookman-May, Sabine D.
    Londhe, Anil
    Bhaumik, Amitabha
    Mundle, Suneel D.
    Larsen, Julie S.
    McCarthy, Sharon A.
    Chi, Kim N.
    FUTURE ONCOLOGY, 2024, 20 (10) : 563 - 578
  • [22] Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.
    Couvillon, Anna
    Turkbey, Baris
    Lindenberg, Maria Liza
    Choyke, Peter L.
    Kaushal, Aradhana
    Citrin, Deborah E.
    Krauze, Andra V.
    McNally, Deborah
    McKinney, Yolanda
    Martinez, Mirna
    Han, Hui
    Karzai, Fatima
    Parnes, Howard L.
    Pinto, Peter A.
    Gulley, James L.
    Dahut, William L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.
    Glaser, Zachary A.
    Avulova, Svetlana
    Stocks, Blair
    Penson, David F.
    Moses, Kelvin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [24] Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.
    Couvillon, Anna
    Turkbey, Baris
    Lindenberg, Maria Liza
    Choyke, Peter L.
    Martinez, Mirna
    McKinney, Yolanda
    Kaushal, Aradhana
    Citrin, Deborah E.
    Krauze, Andra
    McNally, Deborah
    Giordano, Luz
    Chun, Guinevere
    Royce, Cheryl
    Han, Hui
    Karzai, Fatima
    Parnes, Howard L.
    Pinto, Peter A.
    Gulley, James L.
    Dahut, William L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [25] Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
    Rescigno, Pasquale
    Lorente, David
    Bianchini, Diletta
    Ferraldeschi, Roberta
    Kolinsky, Michael P.
    Sideris, Spyridon
    Zafeiriou, Zafeiris
    Sumanasuriya, Semini
    Smith, Alan D.
    Mehra, Niven
    Jayaram, Anuradha
    Perez-Lopez, Raquel
    Mateo, Joaquin
    Parker, Chris
    Dearnaley, David P.
    Tunariu, Nina
    Reid, Alison
    Attard, Gerhardt
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2016, 70 (05) : 724 - 731
  • [26] Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
    Sutera, P.
    Deek, M. P.
    Guler, O. C.
    Hurmuz, P.
    Reyhan, M.
    Rowe, S.
    Hrinivich, W. T.
    Ren, L.
    Song, D.
    Kiess, A. P.
    Oymak, E.
    Pienta, K.
    Pomper, M. G.
    Feng, F. Y.
    Ozyigit, G.
    Tran, P. T.
    Phillips, R.
    Onal, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S109 - S110
  • [27] Prostate-specific antigen (PSA) response in Black patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus abiraterone acetate (ABI): A real-world comparison.
    Brown, Gordon Andrew
    Du, Shawn
    Khilfeh, Ibrahim
    Rossi, Carmine
    Burbage, Sabree
    Kinkead, Frederic
    Diaz, Lilian
    Pilon, Dominic
    Lowentritt, Benjamin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [28] Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer
    McArdle, Peter A.
    Mir, Khurram
    Almushatat, A. S. K.
    Wallace, A. Michael
    Underwood, Mark A.
    McMillan, Donald C.
    UROLOGIA INTERNATIONALIS, 2006, 77 (02) : 127 - 129
  • [29] Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
    Loberg, RD
    Fielhauer, JR
    Pienta, BA
    Dresden, S
    Christmas, P
    Kalikin, LM
    Olson, KB
    Pienta, KJ
    UROLOGY, 2003, 62 (6B) : 128 - 133
  • [30] Real-world (RW) comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus enzalutamide (ENZ)
    Lowentritt, Benjamin H.
    Khilfeh, Ibrahim
    Pilon, Dominic
    Du, Shawn
    Rossi, Carmine
    Kinkead, Frederic
    Diaz, Lilian
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345